α4β7 integrin inhibitors: a patent review

Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease

(2018) M. T. Tang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A Review on Clinical Pharmacokinetics, Pharmacodynamics, and pharmacogenomics of natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody

(2018) Li Hao et al.   CURRENT DRUG METABOLISM

New treatment options for inflammatory bowel diseases

(2018) Bram Verstockt et al.   JOURNAL OF GASTROENTEROLOGY

Development of Endocyclic Control Elements for Peptide Macrocycles

(2018) Solomon D. Appavoo et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Multiple Sclerosis

(2018) Daniel S. Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in inflammatory bowel disease: Novel and emerging treatments

(2018) Ignacio Catalan-Serra et al.   Human Vaccines & Immunotherapeutics

The Role of Integrin α4β7 in HIV Pathogenesis and Treatment

(2018) James Arthos et al.   Current HIV/AIDS Reports

DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs

(2018) Samantha Deianira Dattoli et al.   BRITISH JOURNAL OF PHARMACOLOGY

The safety of vedolizumab for the treatment of ulcerative colitis

(2017) Gregor Novak et al.   Expert Opinion On Drug Safety

The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohnʼs Disease Effector T Cells In Vivo

(2017) Sebastian Zundler et al.   INFLAMMATORY BOWEL DISEASES

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification

(2017) Kalliopi Pitarokoili et al.   Nature Reviews Neurology

Glycosylation and oligomeric state of envelope protein might influence HIV-1 virion capture by α4β7 integrin

(2017) Subhash Chand et al.   VIROLOGY

Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry

(2017) Amber N. Woods et al.   Cancer Immunology Research

Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges

(2017) Marcel Vetter et al.   Therapeutic Advances in Gastroenterology

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

(2017) Sebastian Zundler et al.   Frontiers in Immunology

Transporters for Antiretroviral Drugs in Colorectal CD4+ T Cells and Circulating α4β7 Integrin CD4+ T Cells: Implications for HIV Microbicides

(2016) Indrani Mukhopadhya et al.   MOLECULAR PHARMACEUTICS

Integrin-based therapeutics: biological basis, clinical use and new drugs

(2016) Klaus Ley et al.   NATURE REVIEWS DRUG DISCOVERY

Integrins and adhesion molecules as targets to treat inflammatory bowel disease

(2015) Ivana Bravatà et al.   CURRENT OPINION IN PHARMACOLOGY

Advances in pharmacotherapy for allergic conjunctivitis

(2015) Mark B Abelson et al.   EXPERT OPINION ON PHARMACOTHERAPY

Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis

(2015) Naoki Yoshimura et al.   GASTROENTEROLOGY

Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease

(2015) Lianjie Lin et al.   MEDICINE

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication

(2015) Simone I Richardson et al.   Retrovirology

Dehydro-β-proline Containing α4β1 Integrin Antagonists: Stereochemical Recognition in Ligand–Receptor Interplay

(2015) Alessandra Tolomelli et al.   ACS Medicinal Chemistry Letters

Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7monoclonal antibody, for treating inflammatory bowel diseases

(2014) Wei-Jian Pan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

New Drugs on the Horizon for IBD

(2014) Bruce E. Sands   DIGESTIVE DISEASES

Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases

(2014) Silvio Danese et al.   GASTROENTEROLOGY

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

(2014) Tim Wyant et al.   GUT

Etrolizumab in moderate-to-severe ulcerative colitis

(2014) Alessandro Armuzzi et al.   LANCET

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

(2014) Aurelien Amiot et al.   Therapeutic Advances in Gastroenterology

Orally available and efficacious α4β1/α4β7 integrin inhibitors

(2013) Ying-zi Xu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pharmacology of AMG 181, a human anti-α4β7antibody that specifically alters trafficking of gut-homing T cells

(2013) WJ Pan et al.   BRITISH JOURNAL OF PHARMACOLOGY

Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice

(2013) Toshihiko Sugiura et al.   Journal of Crohns & Colitis

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners

(2013) Victor Pena-Cruz et al.   Retrovirology

Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis

(2012) Kavinderjit S Nanda et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Synthesis and biological evaluation of tyrosine modified analogues of the α4β7 integrin inhibitor biotin-R8ERY

(2012) Stefanie Papst et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tyrosine modified analogues of the α4β7 integrin inhibitor biotin-R8ERY prepared via Click Chemistry: Synthesis and biological evaluation

(2012) Stefanie Papst et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists

(2012) Jefferson W. Tilley et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection

(2012) S. Elahi et al.   BLOOD

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

(2012) Paul J Rutgeerts et al.   GUT

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

(2011) S. Vermeire et al.   GUT

HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV

(2011) Claudia Cicala et al.   Journal of Translational Medicine

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

(2011) Saskia Thomas et al.   INFLAMMOPHARMACOLOGY

α4β7 integrin/MAdCAM-1 adhesion pathway is crucial for B cell migration into pancreatic lymph nodes in nonobese diabetic mice

(2010) Baohui Xu et al.   JOURNAL OF AUTOIMMUNITY

Mutation at a Single Position in the V2 Domain of the HIV-1 Envelope Protein Confers Neutralization Sensitivity to a Highly Neutralization-Resistant Virus

(2010) S. M. O'Rourke et al.   JOURNAL OF VIROLOGY

Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention

(2009) G. Gorfu et al.   CURRENT MOLECULAR MEDICINE

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

The integrin  4 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1

(2009) C. Cicala et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Engineering Principles and Applications

(2008) LiNa Loo et al.   CANCER JOURNAL

Selective cell adhesion inhibitors: Barbituric acid based α4β7—MAdCAM inhibitors

(2007) Geraldine C. Harriman et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A small molecule, orally active, α4β1/α4β7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats

(2006) Julio Cortijo et al.   BRITISH JOURNAL OF PHARMACOLOGY